<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nefr</journal-id><journal-title-group><journal-title xml:lang="ru">Нефрология</journal-title><trans-title-group xml:lang="en"><trans-title>Nephrology (Saint-Petersburg)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1561-6274</issn><issn pub-type="epub">2541-9439</issn><publisher><publisher-name>Pavlov First Saint-Petersburg State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24884/1561-6274-2019-23-4-88-95</article-id><article-id custom-type="elpub" pub-id-type="custom">nefr-1726</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ. ЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES. EXPERIMENTAL INVESTIGATION</subject></subj-group></article-categories><title-group><article-title>Изменение реактивности сосудов крыс с экспериментальным уменьшением массы функционирующих нефронов</article-title><trans-title-group xml:lang="en"><trans-title>Changes in the reactivity of vessels of rats with an experimental decrease in the mass of functioning nephrons</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Иванова</surname><given-names>Г. Т.</given-names></name><name name-style="western" xml:lang="en"><surname>Ivanova</surname><given-names>G. T.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Иванова Галина Тажимовна - кандидат биологических наук, лаборатория физиологии сердечно-сосудистой и лимфатической систем, старший научный сотрудник.</p><p>199034, Санкт-Петербург, наб. Макарова, д. 6, Тел.: 8 (812) 328-07-01</p></bio><bio xml:lang="en"><p>Ivanova Galina Tazhimovna – PhD, senior researcher.</p><p>199034, Saint-Petersburg, Makarova Emb., 6, Phone: 8 (812) 328-07-01</p></bio><email xlink:type="simple">tazhim@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лобов</surname><given-names>Г. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Lobov</surname><given-names>G. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лобов Геннадий Иванович - докор медицинских наук, профессор, лаборатория физиологии сердечно-сосудистой и лимфатической систем, заведующий лабораторией.</p><p>199034, Санкт-Петербург, наб. Макарова, д. 6, Тел.: +7 921 743-06-08</p></bio><bio xml:lang="en"><p>Lobov Gennadii Ivanovich - PhD, DMedSci, head of laboratory.</p><p>199934, Saint-Petersburg, Makarova Emb., 6, Ph. +7 921 7430608</p></bio><email xlink:type="simple">LobovGI@infran.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7532-2405</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Береснева</surname><given-names>О. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Beresneva</surname><given-names>O. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Береснева Ольга Николаевна - кандидат биологических наук, старший научный сотрудник</p><p>197022, Санкт-Петербург, ул. Л. Толстого, д. 17, корп. 54, Тел.: (812) 346-39-26</p></bio><bio xml:lang="en"><p>Olga N. Beresneva - PhD, Nephrology Laboratory of Clinical Physiology of the Kidney, senior researcher.</p><p>197022, St-Petersburg , L.Tolstoy st., 17, build. 54, Phone (812)346-39-26</p></bio><email xlink:type="simple">beresnevaolga@list.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Парастаева</surname><given-names>М. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Parastaeva</surname><given-names>M. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Парастаева Марина Магрезовна - кандидат биологических наук, лаборатория клинической физиологии почек, старший научный сотрудник.</p><p>197022, Санкт-Петербург, ул. Л. Толстого, д. 17, корп. 54, Тел.: (812) 346-39-26</p></bio><bio xml:lang="en"><p>Marina M. Parastaeva - PhD, Nephrology Laboratory of Clinical Physiology of the Kidney senior researcher.</p><p>197022, St-Petersburg, L.Tolstoy st., 17, build. 54, Phone (812)346-39-26</p></bio><email xlink:type="simple">marina_parastaeva@list.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Институт физиологии им. И.П. Павлова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.P Pavlov Institute of Physiology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Научно-исследовательский институт нефрологии, Первый Санкт-Петербургский государственный медицинский университет им. И.П. Павлова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Institute of Nephrology, First Pavlov St.-Petersburg State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>23</day><month>06</month><year>2019</year></pub-date><volume>23</volume><issue>4</issue><fpage>88</fpage><lpage>95</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Иванова Г.Т., Лобов Г.И., Береснева О.Н., Парастаева М.М., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Иванова Г.Т., Лобов Г.И., Береснева О.Н., Парастаева М.М.</copyright-holder><copyright-holder xml:lang="en">Ivanova G.T., Lobov G.I., Beresneva O.N., Parastaeva M.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nephrolog.ru/jour/article/view/1726">https://journal.nephrolog.ru/jour/article/view/1726</self-uri><abstract><sec><title>Цель</title><p>Цель: оценить изменения эндотелийзависимой регуляции тонуса кровеносных сосудов (аорты и верхней брыжеечной артерии) у крыс через 4 месяца после удаления 5/6 почечной ткани.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Модель ХБП создавали резекцией 5/6 массы почечной ткани. В экспериментальную группу вошли животные (n=12), подвергнутые нефрэкто-мии (НЭ). Контрольную группу составили ложнооперированные (ЛО) крысы (n=10). Исследования реактивности сосудов проводили на кольцевых сегментах длиной 2 мм, которые вырезали из аорты и верхней брыжеечной артерии (ВБА). Всего было подготовлено 23 сегмента аорты и 17 сегментов ВБА от крыс после НЭ и 18 сегментов аорты и 15 сегментов ВБА от контрольных животных. Для измерения силы сокращений препаратов использовали датчик FORT-10 (WPI, USA). Оценивали амплитуду ответов сосудов, предварительно сокращенных фенилэфрином (1 *10-5 М ), на ацетилхолин (АХ, 1 *10-6 М), а также реакцию на АХ в условиях предварительного воздействия ТЭА (1 x10-3 М) и L-NAME (1 x10-4 М).</p></sec><sec><title>Результаты</title><p>Результаты. Через 4 месяца после резекции части почечной ткани у крыс развивались артериальная гипертензия - АД в группе НЭ крыс было выше (165, 0±9,8 мм рт.ст) по сравнению с ЛО (127,2±9,7 мм рт. ст., р&lt;0,001), и ремоделирование миокарда (ИММЛЖ у НЭ крыс составлял 2,72±0,11 мг/г по сравнению с 2,35±0,09 мг/ в ЛО группе, р&lt;0,001). НЭ также приводила к уменьшению дилатация фрагментов аорты и ВБА на АХ по сравнению с ЛО животными. В условиях блокады синтеза NO ингибитором NO- синтазы - L-NAME реакция на АХ также была ниже у крыс с НЭ. Предварительная блокада Ca2+-активируемых К+-каналов большой проводимости введением ТЭА приводила к снижению вазодилатации, вызванной АХ, у НЭ крыс по сравнению с ЛО группой.</p></sec><sec><title>Заключение</title><p>Заключение. Резекция 5/6 массы ткани почек у крыс вызывает снижение реактивности сосудов на АХ. Дисрегуляция тонуса сосудов связана с нарушением продукции/биодоступности NO, синтезируемого эндотелием и ингибированием механизма эндотелиальной гиперполяризации.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>The aim</title><p>The aim: to evaluate changes in endothelium-dependent regulation of the tone of blood vessels (aorta and superior mesenteric artery) in rats 4 months after the removal of 5/6 renal tissue.</p></sec><sec><title>Material and methods</title><p>Material and methods. An experimental CKD model was created by resection of 5/6 mass of renal tissue. The experimental group included animals (n = 12), subjected to nephrectomy (NE). The control group consisted of sham-operated (SO) rats (n = 10). Researches of vascular reactivity were performed on ring segments 2 mm long, which were excised from the aorta and superior mesenteric artery (SMA). A total of 23 segments of the aorta and 17 segments of SMA from rats after NE and 18 segments of the aorta and 15 segments of SMA from control animals were prepared. To measure the strength of contractions of the drugs, a FORT-10 sensor (WPI, USA) was used. The effects of acetylcholine (Ach, 1 x10-6 M) on blood vessels, previously exposed to phenylephrine (1 x10-5 M), and the response of vessels to Ach under conditions of prior exposure to TEA (1 x 10-3 mol / l) and L-NAME (1 x10-4 mol / l) were evaluated.</p></sec><sec><title>Results</title><p>Results. NE for a period of 4 months led to arterial hypertension - BP in the NE group of rats was higher (165, 0 ± 9.8 mm Hg) compared with SO (127.2 ± 9.7 mm Hg, р&lt;0,001), and to myocardial remodeling (LVMI in NE rat was 2.72 ± 0.11 mg / g compared to 2.35 ± 0.09 mg / in the SO group, р&lt;0,001 ). NE led to a decrease in dilatation of aortic and BWA fragments on the ACh compared with LO animals. Under the conditions of NO blocking, the NO synthase inhibitor — L-NAME — also had a lower response to ACh in rats with NE. The preliminary blockade of the Ca2 + -activated K + channels of high conductivity with the introduction of TEA resulted in a decrease in vasodilation caused by ACh in NE rat compared with the SO group.</p></sec><sec><title>Conclusion</title><p>Conclusion. Resection of 5/6 of the kidney tissue mass in rats causes a decrease in vascular reactivity on the ACh. Endothelial dysfunction of rats after NE is associated with impairment of both NO-related and hyperpolarization-dependent endothelial cells in pathways of the vascular tone regulation.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>сердечно-сосудистая система</kwd><kwd>нефрэктомия</kwd><kwd>аорта</kwd><kwd>верхняя брыжеечная артерия</kwd><kwd>эндотелиальная дисфункция</kwd><kwd>крысы</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cardiovascular system</kwd><kwd>nephrectomy</kwd><kwd>aorta</kwd><kwd>superior mesenteric artery</kwd><kwd>endothelial dysfunction</kwd><kwd>rats</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена с использованием животных из биоколлекции ИФ РАН</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Смирнов АВ, Добронравов ВА, Каюков ИГ Кардиоренальный континуум: патогенетические основы превентивной нефрологии. Нефрология 2005; 9(3): 7-15</mixed-citation><mixed-citation xml:lang="en">Smirnov AV, Dobronravov VA, Kayukov IG. Kardiorenalnyj continuum: patogeneticheskie osnovy preventivnoj nefrologii. Nefrologiya 2005; 9(3):7-15]</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Di Lullo L, Bellasi A, Barbera V et al. Pathophysiology of the cardio-renal syndromes types 1-5: An uptodate. Indian Heart J 2017; 69(2): 255-265. Doi: 10.1016/j.ihj.2017.01.005</mixed-citation><mixed-citation xml:lang="en">Di Lullo L, Bellasi A, Barbera V et al. Pathophysiology of the cardio-renal syndromes types 1-5: An uptodate. Indian Heart J 2017; 69(2): 255-265. Doi: 10.1016/j.ihj.2017.01.005</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Foley RN, Parfrey PS. Cardiac disease in chronic uremia: clinical outcome and risk factors. Adv Renal Replace Ther 1997; 4: 234-248</mixed-citation><mixed-citation xml:lang="en">Foley RN, Parfrey PS. Cardiac disease in chronic uremia: clinical outcome and risk factors. Adv Renal Replace Ther 1997; 4: 234-248</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305. Doi: 10.1056/NEJMoa041031</mixed-citation><mixed-citation xml:lang="en">Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305. Doi: 10.1056/NEJMoa041031</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ninomiya T, Kiyohara X Kubo M et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int 2005; 68 (1): 228-236</mixed-citation><mixed-citation xml:lang="en">Ninomiya T, Kiyohara X Kubo M et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int 2005; 68 (1): 228-236</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Afsar B, Turkmen K, Covic A, Kanbay M. An update on coronary artery disease and chronic kidney disease. Int J Nephrol 2014; 76(7): 424. Doi: 10.1155/2014/767424</mixed-citation><mixed-citation xml:lang="en">Afsar B, Turkmen K, Covic A, Kanbay M. An update on coronary artery disease and chronic kidney disease. Int J Nephrol 2014; 76(7): 424. Doi: 10.1155/2014/767424</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Choi HX Park HC, Ha SK. How do We manage coronary artery disease in patients with CKD and ESRD? Electrolyte Blood Press 2014; 12 (2): 41-54. Doi: 10.5049/EBP.2014.12.2.41</mixed-citation><mixed-citation xml:lang="en">Choi HX Park HC, Ha SK. How do We manage coronary artery disease in patients with CKD and ESRD? Electrolyte Blood Press 2014; 12 (2): 41-54. Doi: 10.5049/EBP.2014.12.2.41</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Padberg JS, Wiesinger A, di Marco GS. et al. Damage of the endothelial glycocalyx in chronic kidney disease. Atherosclerosis 2014; 234(2): 335-343. Doi: 10.1016/j.atherosclerosis.2014.03.016</mixed-citation><mixed-citation xml:lang="en">Padberg JS, Wiesinger A, di Marco GS. et al. Damage of the endothelial glycocalyx in chronic kidney disease. Atherosclerosis 2014; 234(2): 335-343. Doi: 10.1016/j.atherosclerosis.2014.03.016</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Foley RN, Wang C, Collins AJ. Cardiovascular risk factor profiles and kidney function stage in the US general population: the NHANES III study. Mayo Clin Proc 2005; 80(10): 1270-1277. Doi: 10.4065/80.10.1270</mixed-citation><mixed-citation xml:lang="en">Foley RN, Wang C, Collins AJ. Cardiovascular risk factor profiles and kidney function stage in the US general population: the NHANES III study. Mayo Clin Proc 2005; 80(10): 1270-1277. Doi: 10.4065/80.10.1270</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Baber U, Gutierrez OM, Levitan EB et al. Risk for recurrent coronary heart disease and all-cause mortality among individuals with chronic kidney disease compared with diabetes mellitus, metabolic syndrome, and cigarette smokers. Am Heart J 2013; 166(2): 373-380.e2. Doi: 10.1016/j.ahj</mixed-citation><mixed-citation xml:lang="en">Baber U, Gutierrez OM, Levitan EB et al. Risk for recurrent coronary heart disease and all-cause mortality among individuals with chronic kidney disease compared with diabetes mellitus, metabolic syndrome, and cigarette smokers. Am Heart J 2013; 166(2): 373-380.e2. Doi: 10.1016/j.ahj</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Jimbo R, Shimosawa T Cardiovascular risk factors and chronic kidney disease-FGF23: a key molecule in the cardiovascular disease. Int J Hypertens 2014; 182: 82-98. Doi: 10.1155/2014/381082</mixed-citation><mixed-citation xml:lang="en">Jimbo R, Shimosawa T Cardiovascular risk factors and chronic kidney disease-FGF23: a key molecule in the cardiovascular disease. Int J Hypertens 2014; 182: 82-98. Doi: 10.1155/2014/381082</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Mancia G, Fagard R, Zanchetti A. Reply to blood pressure target in chronic kidney disease. J Hypertens 2013; 31(11): 2321-2322. Doi: 10.1097/HJH.0b013e328365a00a</mixed-citation><mixed-citation xml:lang="en">Mancia G, Fagard R, Zanchetti A. Reply to blood pressure target in chronic kidney disease. J Hypertens 2013; 31(11): 2321-2322. Doi: 10.1097/HJH.0b013e328365a00a</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Карабаева АЖ, Есаян АМ, Каюков ИГ и др. Влияние спи-ронолактона на гипертрофию миокарда левого желудочка у крыс Вистар с экспериментальной уремией. Бюлл экспериментальной биологии и медицины 2008; 145(6): 659-662</mixed-citation><mixed-citation xml:lang="en">Karabaeva AZH, Esayan AM, Kayukov IG i dr. Vliyanie spironolaktona na gipertrofiyu miokarda levogo zheludochka u krys vistar s ehksperimentalnoj uremiej. Byull ehksperimentalnoj biologii I mediciny 2008; 145(6): 659-662</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Каюков ИГ, Береснева ОН, Парастаева ММ и др. Влияние возраста и сокращения массы действующих нефронов на состояние миокарда и коронарного русла у молодых крыс. Регионарное кровообращение и микроциркуляция 2015; 14(4): 66-73</mixed-citation><mixed-citation xml:lang="en">Kayukov IG, Beresneva ON, Parastaeva MM i d . Vliyanie vozrasta i sokrashcheniya massy dejstvuyushchih nefronov na sostoyanie miokarda i koronarnogo rusla u molodyh krys. Regionarnoe krovoobrashchenie imikrocirkulyaciya 2015; 14(4): 66-73</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Maquigussa E, Paterno JC, de Oliveira Pokorny Gh et al. Klotho and PPAR gamma activation mediate the renoprotective effect of losartan in the 5/6 nephrectomy model. Front Physiol 2018; 9: 1033. Doi: 10.3389/fphys.2018.01033</mixed-citation><mixed-citation xml:lang="en">Maquigussa E, Paterno JC, de Oliveira Pokorny Gh et al. Klotho and PPAR gamma activation mediate the renoprotective effect of losartan in the 5/6 nephrectomy model. Front Physiol 2018; 9: 1033. Doi: 10.3389/fphys.2018.01033</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Shobeiri N, Adams MA, Holden RM. Vascular calcification in animal models of CKD: A review. Am J Nephrol 2010; 31(6): 471-481. Doi: 10.1159/000299794</mixed-citation><mixed-citation xml:lang="en">Shobeiri N, Adams MA, Holden RM. Vascular calcification in animal models of CKD: A review. Am J Nephrol 2010; 31(6): 471-481. Doi: 10.1159/000299794</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Claramunt D, Gil-Pefia H, Fuente R et al. Animal models of pediatric chronic kidney disease. Is adenine intake an appropriate model? Nefrologia 2015; 35(6): 517-522. Doi: 10.1016/j.nefro.2015.08.004</mixed-citation><mixed-citation xml:lang="en">Claramunt D, Gil-Pefia H, Fuente R et al. Animal models of pediatric chronic kidney disease. Is adenine intake an appropriate model? Nefrologia 2015; 35(6): 517-522. Doi: 10.1016/j.nefro.2015.08.004</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Лобов ГИ, Васина ЕЮ, Малахова ЗЛ, Власов ТД. Роль различных эндотелиальных вазодилататоров в регуляции тонуса артерий у крыс. Росс физиолжурн им ИМ Сеченова 2018; 104 (3): 327-337</mixed-citation><mixed-citation xml:lang="en">Lobov GI, Vasina EYU, Malahova ZL, Vlasov TD. Rol razlichnyh ehndotelialnyh vazodilatatorov v regulyacii tonusa arterij u krys. Ross fiziolzhurn im IMSechenova 2018; 104 (3): 327-337</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Kang KT Endothelium-derived relaxing factors of small resistance arteries in hypertension. Toxicol Res 2014; 30(3): 141-148. Doi: 10.5487/TR.2014.30.3.141</mixed-citation><mixed-citation xml:lang="en">Kang KT Endothelium-derived relaxing factors of small resistance arteries in hypertension. Toxicol Res 2014; 30(3): 141-148. Doi: 10.5487/TR.2014.30.3.141</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Scotland RS, Madhani M, Chauhan S, Moncada S et al. Investigation of vascular responses in endothelial nitric oxide synthase/cyclooxygenase-1 double-knockout mice: key role for endothelium-derived hyperpolarizing factor in the regulation of blood pressure in vivo. Circulation 2005; 111(6): 796-803. Doi: 10.1161/01.CIR.0000155238.70797.4E</mixed-citation><mixed-citation xml:lang="en">Scotland RS, Madhani M, Chauhan S, Moncada S et al. Investigation of vascular responses in endothelial nitric oxide synthase/cyclooxygenase-1 double-knockout mice: key role for endothelium-derived hyperpolarizing factor in the regulation of blood pressure in vivo. Circulation 2005; 111(6): 796-803. Doi: 10.1161/01.CIR.0000155238.70797.4E</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Huang MJ, Wei RB, Zhao J et al. Albuminuria and endothelial dysfunction in patients with non-diabetic chronic kidney disease. Med Sci Monit 2017; 23: 4447-4453. Doi: 10.12659/MSM.903660</mixed-citation><mixed-citation xml:lang="en">Huang MJ, Wei RB, Zhao J et al. Albuminuria and endothelial dysfunction in patients with non-diabetic chronic kidney disease. Med Sci Monit 2017; 23: 4447-4453. Doi: 10.12659/MSM.903660</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Fujii H, Kono K, Nishi S. Characteristics of coronary artery disease in chronic kidney disease. Clin Exp Nephrol 2019; Doi: 10.1007/s10157-019-01718-5</mixed-citation><mixed-citation xml:lang="en">Fujii H, Kono K, Nishi S. Characteristics of coronary artery disease in chronic kidney disease. Clin Exp Nephrol 2019; Doi: 10.1007/s10157-019-01718-5</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Widlansky ME, Gokce N, Keaney JF, Vita JA. The clinical implications of endothelial dysfunction. Journal of the American College of Cardiology 2003; 42(7): 1149-1160 Doi:10.1016/S0735-1097(03)00994-X</mixed-citation><mixed-citation xml:lang="en">Widlansky ME, Gokce N, Keaney JF, Vita JA. The clinical implications of endothelial dysfunction. Journal of the American College of Cardiology 2003; 42(7): 1149-1160 Doi:10.1016/S0735-1097(03)00994-X</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Smiljic S. The clinical significance of endocardial endothelial dysfunction. Medicina 2017; 53(5): 295-302. Doi: 10.1016/j.medici.2017.08.003</mixed-citation><mixed-citation xml:lang="en">Smiljic S. The clinical significance of endocardial endothelial dysfunction. Medicina 2017; 53(5): 295-302. Doi: 10.1016/j.medici.2017.08.003</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Martens CR, Kuczmarski JM, Lennon-Edwards S, Edwards DG. Impaired L-arginine uptake but not arginase contributes to endothelial dysfunction in rats with chronic kidney disease. J Cardiovasc Pharmacol 2014; 63(1): 40-48. Doi: 10.1097/FJC.0000000000000022</mixed-citation><mixed-citation xml:lang="en">Martens CR, Kuczmarski JM, Lennon-Edwards S, Edwards DG. Impaired L-arginine uptake but not arginase contributes to endothelial dysfunction in rats with chronic kidney disease. J Cardiovasc Pharmacol 2014; 63(1): 40-48. Doi: 10.1097/FJC.0000000000000022</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Li T, Gua C, Wu B, Chen Y Increased circulating trimethyl-amine N-oxide contributes to endothelial dysfunction in a rat model of chronic kidney disease. Biochem Biophys Res Commun 2018; 495(2): 2071-2077. Doi: 10.1016/j.bbrc.2017.12.069</mixed-citation><mixed-citation xml:lang="en">Li T, Gua C, Wu B, Chen Y Increased circulating trimethyl-amine N-oxide contributes to endothelial dysfunction in a rat model of chronic kidney disease. Biochem Biophys Res Commun 2018; 495(2): 2071-2077. Doi: 10.1016/j.bbrc.2017.12.069</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Zanetti M, Gortan Cappellari G, Barbetta D et al. Omega 3 polyunsaturated fatty acids improve endothelial dysfunction in chronic renal failure: role of eNOS activation and of oxidative stress. Nutrients 2017; 9(8): E895. Doi: 10.3390/nu9080895</mixed-citation><mixed-citation xml:lang="en">Zanetti M, Gortan Cappellari G, Barbetta D et al. Omega 3 polyunsaturated fatty acids improve endothelial dysfunction in chronic renal failure: role of eNOS activation and of oxidative stress. Nutrients 2017; 9(8): E895. Doi: 10.3390/nu9080895</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Панина И Ю, Румянцев АШ, Меншутина МА и др. Особенности функций эндотелия при хронической болезни почек. Обзор литературы и собственные данные. Нефрология 2007; 11(4): 28-46</mixed-citation><mixed-citation xml:lang="en">Panina IY Rumyantsev ASH, Menshutina МА, Achkasova VV, i dr. Osobennosti funktsij ehndoteliya pri khronicheskoj bolezni pochek. Obzor literatury i sobstvennye dannye. Nefrologiya 2007; 11(4): 28-46</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Zoccali C, Mallamaci F, Tripepi G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int 2003; 85: S105-S110. Doi: 10.1046/j.1523-1755.63.s85.25.x</mixed-citation><mixed-citation xml:lang="en">Zoccali C, Mallamaci F, Tripepi G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int 2003; 85: S105-S110. Doi: 10.1046/j.1523-1755.63.s85.25.x</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-376</mixed-citation><mixed-citation xml:lang="en">Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-376</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Boulanger CM, Morrison KJ, Vanhoutte PM . Mediation by M3-muscarinic receptors of both endothelium-dependent contraction and relaxation to acetylcholine in the aorta of the spontaneously hypertensive rat. Br J Pharmacol 1994; 112: 519-524</mixed-citation><mixed-citation xml:lang="en">Boulanger CM, Morrison KJ, Vanhoutte PM . Mediation by M3-muscarinic receptors of both endothelium-dependent contraction and relaxation to acetylcholine in the aorta of the spontaneously hypertensive rat. Br J Pharmacol 1994; 112: 519-524</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Toda N, Ayajiki K, Okamura . Neurogenic and endothelial nitric oxide regulates blood circulation in lingual and other oral tissues. J Cardiovasc Pharmacol 2012; 60: 100-108. Doi: 10.1097/FJC.0b013e318252452a</mixed-citation><mixed-citation xml:lang="en">Toda N, Ayajiki K, Okamura . Neurogenic and endothelial nitric oxide regulates blood circulation in lingual and other oral tissues. J Cardiovasc Pharmacol 2012; 60: 100-108. Doi: 10.1097/FJC.0b013e318252452a</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Michel T, Vanhoutte PM. Cellular signalling and NO production. PflugersArch 2010; 459: 807-816</mixed-citation><mixed-citation xml:lang="en">Michel T, Vanhoutte PM. Cellular signalling and NO production. PflugersArch 2010; 459: 807-816</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Vanhoutte PM , Shimokawa H, Feletou M, Tang EHC. Endothelial dysfunction and vascular disease - a 30th anniversary update. Acta Physiol2017; 219: 22-96. https://Doi.org/10.1111/apha.12646</mixed-citation><mixed-citation xml:lang="en">Vanhoutte PM , Shimokawa H, Feletou M, Tang EHC. Endothelial dysfunction and vascular disease - a 30th anniversary update. Acta Physiol2017; 219: 22-96. https://Doi.org/10.1111/apha.12646</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Береснева ОН, Парастаева ММ, Иванова ГТ и др. Оценка кардиопротективного действия малобелковой соевой диеты и уровень неорганических анионов сыворотки крови у спонтанногипертензивных крыс с нефрэктомией Нефрология 2007; 11(3): 70-76</mixed-citation><mixed-citation xml:lang="en">Beresneva ON, Parastayeva MM, Ivanova GT i dr. Otsenka kardioprotektivnogo deystviya malobelkovoy soyevoy diyety i urovnya neorganicheskikh anionov v syvorotke krovi u spontanno-giperten-zivnykh krys s nefrektomiyey. Nefrologiya 2007; 11 (3): 70-76</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Puzserova A, Bernatova I. Blood pressure regulation in stress: focus on nitric oxide-dependent mechanisms. Physiol Res 2016; 65 (Suppl. 3): S309-S342</mixed-citation><mixed-citation xml:lang="en">Puzserova A, Bernatova I. Blood pressure regulation in stress: focus on nitric oxide-dependent mechanisms. Physiol Res 2016; 65 (Suppl. 3): S309-S342</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Yamamizu K, Shinozaki K, Ayajiki K, et al. Oral administration of both tetrahydrobiopterin and L-arginine prevents endothelial dysfunctionin rats with chronic renal failure. J Cardiovasc Pharmacol 2007; 49(3): 131-139. Doi: 10.1097/FJC.0b013e31802f9923</mixed-citation><mixed-citation xml:lang="en">Yamamizu K, Shinozaki K, Ayajiki K, et al. Oral administration of both tetrahydrobiopterin and L-arginine prevents endothelial dysfunctionin rats with chronic renal failure. J Cardiovasc Pharmacol 2007; 49(3): 131-139. Doi: 10.1097/FJC.0b013e31802f9923</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Xu YC, Leung SW, Leung GP, Man RY Kaempferol enhances endothelium-dependent relaxation in the porcine coronary artery through activation of large-conductance Ca(2+) activated K(+) channels. Br J Pharmacol 2015; 172: 3003-3014. Doi: 10.1111/bph.13108</mixed-citation><mixed-citation xml:lang="en">Xu YC, Leung SW, Leung GP, Man RY Kaempferol enhances endothelium-dependent relaxation in the porcine coronary artery through activation of large-conductance Ca(2+) activated K(+) channels. Br J Pharmacol 2015; 172: 3003-3014. Doi: 10.1111/bph.13108</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Jang HJ, Ridgeway SD, Kim JA. Effects of the green tea polyphenol epigallocatechin-3-gallate on high-fat diet-induced insulin resistance and endothelial dysfunction. Am J Physiol Endocrinol Metab 2013; 305: E1444-E1451</mixed-citation><mixed-citation xml:lang="en">Jang HJ, Ridgeway SD, Kim JA. Effects of the green tea polyphenol epigallocatechin-3-gallate on high-fat diet-induced insulin resistance and endothelial dysfunction. Am J Physiol Endocrinol Metab 2013; 305: E1444-E1451</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Feletou M, Vanhoutt PM. . Endothelium-dependent hyperpolarization: no longer an f-word! J Cardiovasc Pharmacol 2013; 61: 91-92. Doi: 10.1097/FJC.0b013e31828197bc</mixed-citation><mixed-citation xml:lang="en">Feletou M, Vanhoutt PM. . Endothelium-dependent hyperpolarization: no longer an f-word! J Cardiovasc Pharmacol 2013; 61: 91-92. Doi: 10.1097/FJC.0b013e31828197bc</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Shimokawa H. Williams Harvey Lecture: importance of coronary vasomotion abnormalities-from bench to bedside. Eur Heart 2014; J 35: 3180-3193. Doi: 10.1093/eurheartj/ehu427</mixed-citation><mixed-citation xml:lang="en">Shimokawa H. Williams Harvey Lecture: importance of coronary vasomotion abnormalities-from bench to bedside. Eur Heart 2014; J 35: 3180-3193. Doi: 10.1093/eurheartj/ehu427</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Busse R, Edwards M, Feletou M et al. EDHF: Bringing the concepts together. Trends PharmacolSci 2002; 23: 374-380</mixed-citation><mixed-citation xml:lang="en">Busse R, Edwards M, Feletou M et al. EDHF: Bringing the concepts together. Trends PharmacolSci 2002; 23: 374-380</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Eichler I, Wibawa J, Grgic I et al. Selective blockade of endothelial Ca2+-activated small- and intermediate-conductance K+-channels suppresses EDHF-mediated vasodilation. Br J Pharmacol 2003; 138: 594-601 https://Doi.org/10.1038/sj.bjp.0705075</mixed-citation><mixed-citation xml:lang="en">Eichler I, Wibawa J, Grgic I et al. Selective blockade of endothelial Ca2+-activated small- and intermediate-conductance K+-channels suppresses EDHF-mediated vasodilation. Br J Pharmacol 2003; 138: 594-601 https://Doi.org/10.1038/sj.bjp.0705075</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Edwards G, Dora KA, Gardener MJ, et al. K+ is an endothelium-derived hyperpolarizing factor in rat arteries. Nature 1998; 396: 269-272 https://Doi.org/10.1038/24388</mixed-citation><mixed-citation xml:lang="en">Edwards G, Dora KA, Gardener MJ, et al. K+ is an endothelium-derived hyperpolarizing factor in rat arteries. Nature 1998; 396: 269-272 https://Doi.org/10.1038/24388</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Griffith TM, Chaytor AT, Taylo HJ, et al. cAMP facilitates EDHF-type relaxations in conduit arteries by enhancing electronic conduction via gap junctions. Proc Natl Acad Sci USA 2002; 99: 6392-6397 https://Doi.org/10.1073/pnas.092089799</mixed-citation><mixed-citation xml:lang="en">Griffith TM, Chaytor AT, Taylo HJ, et al. cAMP facilitates EDHF-type relaxations in conduit arteries by enhancing electronic conduction via gap junctions. Proc Natl Acad Sci USA 2002; 99: 6392-6397 https://Doi.org/10.1073/pnas.092089799</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Kohler R, Eichler I, Schonfelder H et al. Impaired EDHF-mediated vasodilation and function of endothelial Ca-activated K channels in uremic rats. Kidney Int 2005; 67(6): 2280-2287. Doi: 10.1111/j.1523-1755.2005.00331.x</mixed-citation><mixed-citation xml:lang="en">Kohler R, Eichler I, Schonfelder H et al. Impaired EDHF-mediated vasodilation and function of endothelial Ca-activated K channels in uremic rats. Kidney Int 2005; 67(6): 2280-2287. Doi: 10.1111/j.1523-1755.2005.00331.x</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Li T, Gua C, Wu B, Chen Y Increased circulating trimethyl-amine N-oxide contributes to endothelial dysfunction in a rat model of chronic kidney disease. Biochem Biophys Res Commun 2018; 495(2): 2071-2077. Doi: 10.1016/j.bbrc.2017.12.069</mixed-citation><mixed-citation xml:lang="en">Li T, Gua C, Wu B, Chen Y Increased circulating trimethyl-amine N-oxide contributes to endothelial dysfunction in a rat model of chronic kidney disease. Biochem Biophys Res Commun 2018; 495(2): 2071-2077. Doi: 10.1016/j.bbrc.2017.12.069</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
